| Theme | Diagnosis and Treatment of Barrett's Esophagus : up-to-date | |
|---|---|---|
| Title | Drug Treatment for Barrett's Esophagus | |
| Publish Date | 2014/06 | |
| Author | Satoshi Harada | Department of Internal Medicine II, Osaka Medical College |
| Author | Toshihisa Takeuchi | Department of Internal Medicine II, Osaka Medical College |
| Author | Kazuhiro Ota | Department of Internal Medicine II, Osaka Medical College |
| Author | Shoko Edogawa | Department of Internal Medicine II, Osaka Medical College |
| Author | Yuichi Kojima | Department of Internal Medicine II, Osaka Medical College |
| Author | Kazuhide Higuchi | Department of Internal Medicine II, Osaka Medical College |
| [ Summary ] | Barrett's esophagus is known to be a risk factor for esophageal adenocarcinoma. This condition has increased in Japan with the westernization of eating habits and declines in infection rates from Helicobacter pylori. NSAIDs, such as aspirin, and COX-2 are being investigated to prevent the incidence of Barrett's esophagus. In western countries, many clinical studies related to prevention of Barrett's esophagus and esophageal adenocarcinoma have been performed. These studies have demonstrated that NSAIDs or PPIs reduce the incidence of Barrett's esophagus and esophageal adenocarcinoma. It is expected that the incidence of esophageal adenocarcinoma will increase in Japan because of the increase of Barrett's esophagus. Therefore, even in Japan, investigations related to prevention of Barrett's esophagus and esophageal adenocarcinoma are required. | |